Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies
There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetes mellitus. It is hypothesized that these benefits are mediated by mechanisms other than glucose control. To address this, w...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2019
|
| Online Access: | http://hdl.handle.net/20.500.11937/74153 |